Angiotensin-converting Enzyme Insertion/deletion Polymorphism And The Risk Of Prostate Cancer In The Han Population Of China

ObjectiveAs a main effector in the renin-angiotensin system, the angiotensin Ⅱ plays a critical role in cell proliferation and angiogenesis. The change between angiotensin Ⅱ and its precursor is conducted by the angiotensin-converting enzyme. The association between angiotensin-converting enzyme insertion/deletion polymorphism and the activity of angiotensin-converting enzyme was testified. Furthermore, previous researches proved the association between angiotensin-converting enzyme activity and the risk of prostate cancer. Therefore, we conducted a case-control study in the Han population of China to elaborate the relationship between the angiotensin-converting enzyme insertion/deletion polymorphism and prostate cancer risk.Method:DNA was extracted from blood samples collected from189pathologically diagnosed prostate cancer patients and290cancer-free subjects. The angiotensin-converting enzyme insertion/deletion genotype was determined by polymerase chain reaction analysis. Stratified analyses on age (<71or≥71),cancer stage (localized or advanced), Gleason score (≤7or>7) and PSA level (≤20ng/ml or>20ng/ml) were performed.Result:We found the Ⅱ genotype (OR=0.304,95%CI (0.180-0.515), p<0.001) and Ⅰ allele (OR=0.547,95%CI (0.421-0.711), p<0.001) were associated with a decreased risk of prostate cancer compared with the DD genotype and D allele. The DD genotype was related to patients with aggressive stage of prostate cancer (OR=2.214,95%CI (1.169-4.194), p=0.014) and patients diagnosed of prostate cancer at a relatively early age (OR=0.513,95%CI (0.272-0.965), p=0.037).Conclusion:The results of our experiment supported the hypothesis that the angiotensin-converting enzyme insertion/deletion polymorphism, a potential risk factor in carcinogenesis, played an important role in the Han population of China.